Drugs for improving esophageal mucosa defense: where are we now and where are we going?

In the past, the attention of physiologists and doctors has been mainly focused on the key role of acid in the pathogenesis of gastroesophageal reflux disease (GERD), but increasing evidence that 20-40% of reflux patients respond not at all or only partially to proton pump inhibitors (PPIs) has unde...

Descripción completa

Detalles Bibliográficos
Autores principales: Savarino, Edoardo, Zentilin, Patrizia, Marabotto, Elisa, Pellegatta, Gaia, Coppo, Claudia, Brunacci, Matteo, Dulbecco, Pietro, Savarino, Vincenzo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hellenic Society of Gastroenterology 2017
Materias:
Invited Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5670277/
https://www.ncbi.nlm.nih.gov/pubmed/29118552
http://dx.doi.org/10.20524/aog.2017.0187

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5670277/
https://www.ncbi.nlm.nih.gov/pubmed/29118552
http://dx.doi.org/10.20524/aog.2017.0187

Ejemplares similares